Human Immunology News 5.33 August 22, 2017 | |
| |
TOP STORYScientists evaluated the safety and efficacy of an adoptive CD4+ T-cell therapy using a major histocompatibility complex class II–restricted, HLA-DPB1*0401–restricted T-cell receptor that recognized the cancer germline antigen, MAGE-A3. [J Clin Oncol] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers isolated monocytes from 134 genotyped individuals, stimulated these cells with three defined microbe-associated molecular patterns, and profiled the transcriptomes at three time points. [Nat Commun] Full Article Immune Evasion by a Staphylococcal Inhibitor of Myeloperoxidase With the aid of secretome phage display, investigators identified a highly conserved protein that specifically binds and inhibits human myeloperoxidase, a major player in the oxidative defense of neutrophils. They named this protein “staphylococcal peroxidase inhibitor”. [Proc Natl Acad Sci USA] Full Article Apoptotic Resistance of Human Skin Mast Cells Is Mediated by Mcl-1 The authors report that naturally differentiated skin mast cells exhibit substantial resilience to cell death with considerable portions surviving up to three days in the complete absence of growth factors. [Cell Death Dis] Full Article Human Mucosal-Associated Invariant T (MAIT) Cells Possess Capacity for B-Cell Help The authors investigated the effect of human MAIT cells on B cells ex vivo. They found that supernatants from microbe- or cytokine-stimulated MAIT cells, when added to purified autologous B cells, increased frequencies of plasmablasts and promote IgA, IgG, and IgM production. [J Leukoc Biol] Abstract The GMP-conform manufacturing of clinical-grade natural killer (NK) cells at sufficiently high numbers represent a great challenge. The authors improved and optimized previous expansion protocols for those effector cells through the use of newly developed culture medium, IL-21 and autologous feeder cells. [Hum Gene Ther] Abstract IFNA-AS1 Regulates CD4+ T Cell Activation in Myasthenia Gravis though HLA-DRB1 Investigators discovered that the lncRNA IFNG-AS1 is abnormally expressed in myasthenia gravis (MG) patients associated with quantitative MG and the positive anti-AchR Ab levels patients. IFNG-AS1 influenced Th1/Treg cell proliferation and regulated the expression levels of their transcription factors in an experimental autoimmune MG model. [Clin Immunol] Abstract Maturation-Dependent Expression of AIM2 in Human B-Cells Scientists investigated the expression of absent in melanoma 2 (AIM2) in different cell types derived from human cord and adult peripheral blood, in steady state and following in vitro-activation. [PLoS One] Full Article Effects of Fusariotoxin Co-Exposure on THP-1 Human Immune Cells Four relevant fusariotoxin mixtures, namely DON-MON, DON-FB1, DON-ZEA, and NIV-T2, were studied using several parameters including cell viability as well as the expression of cell surface markers and the main mitogen-activated protein kinases. [Cell Biol Toxicol] Abstract Researchers describe Takinib, a potent and selective TAK1 inhibitor that induces apoptosis following tumor necrosis factor alpha (TNF-α) stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. [Cell Chem Biol] Abstract | Graphical Abstract Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSHuman Immune System Mouse Models of Ebola Virus Infection The authors review existing models, discuss their use in pathogenesis studies and therapeutic screening, and highlight considerations for study design and analysis. They point out caveats to current models, and recommend future efforts for modeling Ebola virus infection in human immune system mice. [Curr Opin Virol] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSUCART123 Is First US Gene Edited, Off-the-Shelf CAR T-Cell Program Cellectis announced that the first patient with Blastic Plasmacytoid Dendritic Cell Neoplasm has been dosed in Cellectis’ Phase I clinical study using the company’s wholly controlled TALEN® gene edited product candidate UCART123 at the MD Anderson Cancer Center. [Cellectis] Press Release Ocugen, Inc. announced the FDA has granted orphan drug designation for OCU300 for the treatment of ocular graft versus host disease. [Ocugen, Inc.] Press Release Protalex, Inc. announced that the FDA Office of Orphan Products Development has awarded the company a $403,000 grant to support future clinical development activity of PRTX-100 as a treatment for immune thrombocytopenia. [Protalex, Inc.] Press Release The FDA has granted two orphan drug designations for T cell therapy products to Lion TCR Pte Ltd., for the treatment of hepatocellular carcinoma. [Lion TCR Pte Ltd. (PR Newswire Association LLC.)] Press Release Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody Grid Therapeutics, LLC. announced the execution of an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer. [Grid Therapeutics, LLC. (Business Wire, Inc.)] Press Release | |
| |
POLICY NEWSNSF Reiterates Policy on Teaching Good Research Habits despite Its Limitations The National Science Foundation (NSF) in Arlington, Virginia, has decided to double down on its implementation of a congressionally mandated policy aimed at reducing research misconduct among NSF-funded scientists, despite a new report that notes problems with the agency’s approach. [ScienceInsider] Editorial Trump Offers His First List of Science Priorities, and It’s America First President Donald Trump has translated his campaign promise to “make America great again” into his administration’s first blueprint for federal investment in science and technology. [ScienceInsider] Editorial
| |
EVENTSNEW Cell-Weizmann Institute of Science Symposium: Next Gen Immunology Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Immunology Cell Based Assay (Turnstone Biologics Inc.) Protein Engineering Scientists – Oncology, Autoimmune and Infectious Diseases (Immunocore) Postdoctoral Scholar – Regulation of Immune Responses (University of Iowa) Postdoctoral Fellowships – Immune Signaling and Metabolism (St. Jude Children’s Research Hospital) Postdoctoral Research Fellow – Immunology (Harvard Medical School, Joslin Diabetes Center) Postdoctoral Researcher – Inflammatory Diseases (University of Pennsylvania) Assistant Professor – Cell Science (University of Manitoba) Postdoctoral Fellow – B Cells in Autoimmune Diseases (Inserm) Postdoctoral Position – Molecular Biology and Immunology (Harvard Medical School) Postdoctoral Research Fellow – Cancer Immunotherapy (Fred Hutchinson Cancer Research Center) Postdoctoral Fellow – Neuroimmunology (Duke University) Postdoctoral Research Fellow – Innate Immunity (Fred Hutchinson Cancer Research Center) Assistant, Associate or Full Member – Cancer Immunology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Human Immunology News Volume 5.33 | Aug 22 2017